



**The Michael J. Fox Foundation for Parkinson's Research & The New York Academy of Sciences**  
 Parkinson's Disease Therapeutics Conference  
 New York, NY | October 24, 2013

<b>Conference Program</b>	
8:30	<b>Breakfast</b>
9:00 – 9:20	<b>Welcome by Todd Sherer, PhD and Warren Olanow, MD, FRCPC</b>
9:20 – 11:00	<p><b>Disease Modifying Therapies</b></p> <p><i>Raymond Bartus, PhD, Ceregene, Inc.</i>            “Results from a Sham-Surgery Controlled Phase 2b Trial Testing AAV2-Neurturin (CERE-120) in Moderately-Advanced Parkinson Disease: What Have We Learned and Where Do We Go from Here?”</p> <p><i>Reina Fuji, VMD, PhD, Genentech, Inc.</i>            “Nonclinical Safety Studies of Selective LRRK2 Kinase Inhibitors”</p> <p><i>Michael A. Schwarzschild, MD, PhD, Harvard Medical School</i>            “Inosine for Parkinson's Disease: Safety and Trial Design Optimization”</p> <p><i>Kimberly S. Gannon, PhD, NeuroPhage Pharmaceuticals, Inc.</i>            “NPT001 Reduces Alpha-Synuclein Deposits and Improves Motor Performance in Alpha-Synuclein Overexpressing Mice”</p>
11:00 – 11:30	<b>Networking Break/Poster Viewing</b>
11:30 – 12:45	<p><b>Symptomatic Therapies</b></p> <p><i>Adrian Newman-Tancredi, PhD, Neurolix, Inc.</i>            “Enhanced Activity in Rodent Models of Parkinsonism and L-DOPA-Induced Dyskinesias by Preferential Targeting of Subpopulations of 5-HT1A Receptors”</p> <p><i>Mary Maral Mouradian, MD, Rutgers - Robert Wood Johnson Medical School</i>            “Development of a New Treatment for LID Targeting Opioid Receptors”</p> <p><i>Ephraim Heller, SynAgile Corporation</i>            “DopaFuse: Development of a Continuously Infused, Subcutaneously Delivered Levodopa Prodrug for the Management of Parkinson's Disease”</p>
12:45 – 1:45	<b>Lunch/Poster Viewing</b>
1:45 – 3:30	<p><b>Research Tools and Resources</b></p> <p><i>Charles H. Adler, MD, PhD, Mayo Clinic Arizona and Arizona Parkinson's Disease Consortium</i>            “Salivary Gland Biopsies as a Diagnostic Test for Parkinson's Disease”</p> <p><i>Peggy Taylor, ScD, Covance Inc.</i>            “Validation of Biomarkers for Parkinson's Disease: the Critical Need for Robust Assays”</p>

	<p><i>Kenneth Marek, MD, The Institute for Neurodegenerative Disorders</i>  “The Parkinson’s Progression Markers Initiative – Developing Tools To Test PD Therapeutics”</p>
3:30 – 4:00	Networking Break/Poster Viewing
4:00 – 5:00	<p>Hot Topics in Parkinson’s Disease Research</p> <p><i>Donald E. Frail, PhD, AstraZeneca PLC</i>  “Accelerating the Development of New Medicines to Patients through Drug Repositioning”</p> <p><i>Eric Siemers, MD, Eli Lilly and Company</i>  “What Have We Learned from Alzheimer’s Disease Trials”</p>
5:00 – 5:15	Closing Remarks
5:15 – 7:00	Cocktail Reception/Poster Viewing